Aizenstein, H.et al. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65, 1509–1517.
Albert, M. S.et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimer's and Dementia, 7, 270–279. doi:10.1016/j.jalz.2011.03.008.
Amariglio, R. E.et al. (2012). Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia, 50, 2880–2886.
Crane, P.et al. (2012). Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior, 6, 502–516. doi:10.1007/s11682-012-9186-z.
Delis, D. C., Kaplan, E. and Kramer, J. H. (2001). The Delis-Kaplan Executive Function System (D-KEFS). San Antonio, TX: Psychological Corporation.
Delis, D., Kramer, J., Kaplan, E. and Ober, B. (2000). California Verbal Learning Test, 2nd Edn.San Antonio, TX: Psychological Corporation.
Dickerson, B. C. and Sperling, R. A. (2008). Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia, 46, 1624–1635. doi:10.1016/j.neuropsychologia.2007.11.030.
Doraiswamy, P. M.et al. (2012). Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology, October 16, 1636–1644.
Dubois, B.et al. (2010). Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology, 9, 1118–1127.
Dubois, B. and Albert, M. L. (2004). Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurology, 3, 246–248. doi:10.1016/s1474-4422(04)00710-0.
Ellis, K. A.et al. (2009). The Australian imaging, biomarkers and lifestyle study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21, 672–687. doi:10.1017/S1041610209009405.
Gibbons, L.et al. (2012). A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior, 6, 517–527. doi:10.1007/s11682-012-9176-1.
Hedden, T., Oh, H., Younger, A. P. and Patel, T. A. (2013). Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology, 80, 1341–1348.
Jack, C. R.et al. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 131, 665–680.
Johnson, J. K., Gross, A., Pa, J., Mclaren, D. G., Park, L. Q. and Manly, J. J. (2012). Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging and Behavior, 6, 540–550. doi:10.1007/s11682-012-9161-8.
Libon, D.J., Swenson, R.A., Barnoski, E.J. and Sands, L.P. (1993). Clock drawing as an assessment tool for dementia. Archives of Clinical Neuropsychology, 8, 405–415.
Mathis, C. A.et al. (2013). In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Annals of Neurology. doi:10.1002/ana.23797.
Meyers, J. E. and Meyers, K. R. (1995). Rey Complex Figure Test and Recognition Trial, Professional Manual. Lutz, FL: Psychological Assessment Resource.
Nuechterlein, K. H.et al. (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability and validity. American Journal of Psychiatry, 165, 203–213.
Pike, K. E.et al. (2007). β-amyloid imaging and memory in non-demented individuals: evidence for pre-clinical Alzheimer's disease. Brain, 130, 2837–2844. doi:10.1093/brain/awm238.
Rowe, C. C.et al. (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31, 1275–1283. doi:10.1016/j.neurobiolaging.2010.04.007.
Saxton, J.et al. (2000). Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clinical Neuropychology, 14, 526–534.
Sperling, R. A.et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's and Dementia, 7, 280–292. doi:10.1016/j.jalz.2011.03.003.
Sperling, R. A.et al. (2013). Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 34, 822–831.
Strauss, E., Sherman, M. S. Elisabeth and Spreen, O. (2006). A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 3rd edn.New York, NY: Oxford University Press.
Villemagne, V. L.et al. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology, 69, 181–192. doi:10.1002/ana.22248.
Wechsler, D. (1945). A standardised memory scale for clinical use. Journal of Psychology, 19, 87–95.
Wechsler, D. (1997). Wechsler Adult Intelligence Scale (WAIS-III), 3rd edn.San Antonio, TX: Psychological Corporation.
Winblad, B.et al. (2004). Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitve Impairment. Journal of Internal Medicine, 256, 240–246.
Yang, L., Rieves, D. and Ganley, C. (2012). Brain amyloid imaging – FDA approval of Florbetapir F18 injection. New England Journal of Medicine, 367, 885–887. doi:10.1056/NEJMp1208061.
Zakzanis, K. K. (2001). Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Archives of Clinical Neuropsychology, 16, 653–667.